Radiopharmaceutical Drug Conjugates / RDC

Radiopharmaceutical drug conjugates, or RDCs, are introduced in 156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 as a radiation version of [[ADCEngineeringOptimization|ADC-like targeted delivery]]. The source’s analogy is that ADCs deliver chemical payloads, while RDCs deliver radioactive payloads to target tissue.

The episode emphasizes operational constraints. Radioactive isotopes have half-lives and regulatory handling requirements, so RDC value depends on manufacturing location, hospital proximity, logistics, radiation-control procedures, and clinical workflow as much as molecular targeting.

Key Claims

• RDCs can be understood as targeted radiotherapy rather than targeted chemotherapy.
• Smaller carriers such as peptides may fit some RDC uses better than antibodies because tissue penetration and timing matter.
• The source says current cancer use concentrates in areas such as prostate cancer and neuroendocrine tumors.
• Supply-chain and regulatory execution are core capability tests, not afterthoughts.

Connections

• ADC Engineering Optimization - analogy and contrast.
• Clinical Development Capability and Global Pharma Commercialization - evidence and delivery-system execution.
• Biotech BD Data Validation Phase - modality watch item for 2026.